ReviewEXCLI journal2025
A review on the role of nanoparticles for targeted brain drug delivery: synthesis, characterization, and applications.
Review in EXCLI journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Review
- Pharmacological modulation of cGAS-STING-NLRP3 signaling by nano-immunomodulators in Alzheimer and Parkinson disease.Inflammopharmacology · 2026Review
- Targeted nanotherapeutic strategy for melanoma using silk-fibroin based artemisinin nanoparticles.RSC advances · 2026Article
- Plasma-Nanomedicine Synergistic Therapy for Brain Diseases: Current Status, Applications, and Challenges.Antioxidants (Basel, Switzerland) · 2026Review
- Pathophysiological and Etiological Corroborations for the Mechanistic Design of Intranasal Therapies in Glioblastoma Multiforme.Current pharmaceutical design · 2026Review
- Lactoferrin based copper nanoparticles: a promising anti-cancer strategy against malignant melanoma.Scientific reports · 2025Article
- Enhanced Antimicrobial Activity of Green-SynthesizedFoods (Basel, Switzerland) · 2025Article
- Enhanced Bioavailability of a Thionated IMiD Derivative Nanosuspension for Parkinson's Disease Targeting α-Synuclein.International journal of nanomedicine · 2025Article
- Nanoparticles Loaded with Pralidoxime Wrapped in Tumor Cell Membranes: A New Strategy to Counteract the Central Nervous System Effects of Organophosphate Poisoning.International journal of nanomedicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Unfortunately, nowadays, brain disorders, which include both neurological and mental disorders, are the main cause of years spent living with a disability worldwide. There are serious diseases with a high prevalence and a high mortality rate. However, the outmoded technical infrastructure makes their treatment difficult. The blood-brain barrier (BBB) serves as a protective mechanism for the central nervous system (CNS) and regulates its homeostatic processes. The brain is protected against injury and illness by an extremely complex system that precisely regulates the flow of ions, very few tiny molecules, and an even smaller number of macromolecules from the blood to the brain. Nevertheless, the BBB also considerably inhibits the delivery of medications to the brain, making it impossible to treat a variety of neurological diseases. Several strategies are now being studied to enhance the transport of drugs over the BBB. According to this research, nanoparticles are one of the most promising agents for brain disease treatment while many conventional drugs are also capable of crossing this barrier but there are amazing facts about nanoparticles in brain drug delivery. For example, 1. Precision Targeting: Through mechanisms such as receptor-mediated transport, ligand attachment, or the use of external stimuli (e.g., magnetic or thermal guidance), nanoparticles can deliver drugs specifically to diseased areas of the brain while minimizing exposure to healthy tissues. This targeted approach reduces side effects and enhances therapeutic outcomes. 2. Improved Drug Stability: Drugs can be encapsulated by nanoparticles, which keeps them stable and shields them from deterioration while being transported to the brain. 3. Therapeutic Payload: Nanoparticles possess a high surface-area-to-volume ratio, enabling them to encapsulate a substantial quantity of therapeutic agents relative to their size. This allows for enhanced drug delivery efficiency, maximizing therapeutic outcomes while potentially reducing the required dosage to achieve the desired effect. 4. Imaging Properties: Certain nanoparticles can also act as contrast agents for magnetic resonance imaging (MRI), allowing for the real-time visualization of drug distribution and administration in the brain. 5. Combination Therapy Possibility: Nanoparticles can be designed to co-deliver multiple medications or therapeutic agents, which could enhance synergistic effects. There have been
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.